Immunotherapy of targeting MDSCs in tumor microenvironment

Hongshu Sui, Shengyi Dongye, Xiaocui Liu, Xinghua Xu, Li Wang, Christopher Q. Jin, Minhua Yao, Zhaoqing Gong, Daniel Jiang, Kexin Zhang, Yaling Liu, Hui Liu, Guomin Jiang, Yanping SuFrontiers in Immunology 2022 · DOI

Abstract

Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous cells which are abnormally accumulated during the differentiation of myeloid cells. Immunosuppression is the main functional feature of MDSCs, which inhibit T cell activity in the tumor microenvironment (TME) and promote tumoral immune escape. The main principle for immunotherapy is to modulate, restore, and remodel the plasticity and potential of immune system to have an effective anti-tumor response. In the TME, MDSCs are major obstacles to cancer immunotherapy through reducing the anti-tumor efficacy and making tumor cells more resistant to immunotherapy. Therefore, targeting MDSCs treatment becomes the priority of relevant studies and provides new immunotherapeutic strategy for cancer treatment. In this review, we mainly discuss the functions and mechanisms of MDSCs as well as their functional changes in the TME. Further, we review therapeutic effects of immunotherapy against MDSCs and potential breakthroughs regarding immunotherapy targeting MDSCs and immune checkpoint blockade (ICB) immunotherapy.

Introduction

Immune Checkpoint Blockade (ICB) therapies, specifically those targeting PD-1 or CTLA-4, have fundamentally changed oncology. However, these treatments remain effective for only a minority (15–20%) of patients with solid tumors. A primary driver of this resistance is the Tumor Microenvironment (TME), where the tumor actively recruits immunosuppressive cells to create a protective "shield."

Among these, Myeloid-Derived Suppressor Cells (MDSCs) are central. These immature myeloid cells fail to differentiate into functional macrophages or neutrophils, instead remaining in a pro-tumor state that actively inhibits T cell and Natural Killer (NK) cell activity. Understanding MDSC biology is critical for developing combination therapies that can convert "cold" tumors into "hot" ones responsive to immunotherapy.

Figure 1: Differentiation of MDSCs in normal vs. tumor microenvironments. In tumors, normal myelogenesis is blocked, leading to MDSC accumulation and subsequent inhibition of T and NK cells.

Mechanisms of MDSC-Mediated Immunosuppression

MDSCs utilize a variety of signaling pathways and chemical mediators to disarm the immune system. Key pathways include STAT3, NF-κB, and HIF-1α, which regulate the production of reactive oxygen species (ROS), nitric oxide, and Arginase-1.

Metabolic Hijacking

MDSCs exhibit significant metabolic plasticity, often shifting toward fatty acid oxidation (FAO) and increased glycolysis. This metabolic adaptation allows them to thrive in the nutrient-depleted TME while simultaneously fueling the production of immunosuppressive molecules. This "metabolic hijacking" not only ensures MDSC survival but also actively suppresses the metabolic needs of effector T cells.

Heterogeneity and Plasticity

A significant challenge in targeting MDSCs is their heterogeneity. They are generally categorized into two subsets: granulocytic (PMN-MDSCs) and monocytic (M-MDSCs). Because they share markers with healthy myeloid cells, blanket depletion risks damaging the patient's innate immune system. However, their nature as cells in "arrested development" suggests a therapeutic opportunity: forcing them to differentiate into mature, non-suppressive cells using agents like All-Trans Retinoic Acid (ATRA).

Therapeutic Strategies and Synergy

Targeting MDSCs is most effective when used in combination with ICB. By removing the MDSC-mediated immunosuppressive barrier, T cells activated by checkpoint inhibitors can effectively infiltrate and attack the tumor.

  • Blocking Recruitment: Inhibiting receptors like CXCR2 or CCR5 can prevent PMN-MDSCs from entering the tumor. Preclinical oral cancer models have shown that CXCR2 inhibition significantly enhances anti-PD-1 efficacy.
  • Metabolic Targeting: Inhibiting FAO or the AMPK pathway has been shown to reduce MDSC suppressive function and slow tumor growth.
  • Pharmacological Depletion: Agents such as Entinostat (an HDAC inhibitor) or Cabozantinib (a multikinase inhibitor) have shown promise in reducing MDSC populations and improving overall antitumor activity in clinical settings.

Future Directions

Despite the potential, several hurdles remain. The lack of highly specific markers for human MDSCs makes clinical targeting difficult, and there is a recognized gap between mouse models and human myeloid biology. Future research is likely to focus on immunometabolism—targeting the specific metabolic pathways MDSCs use to survive—and the discovery of better biomarkers to identify patients who would benefit most from MDSC-targeted combination therapies.

Summary updated

Abstract

Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous cells which are abnormally accumulated during the differentiation of myeloid cells. Immunosuppression is the main functional feature of MDSCs, which inhibit T cell activity in the tumor microenvironment (TME) and promote tumoral immune escape. The main principle for immunotherapy is to modulate, restore, and remodel the plasticity and potential of immune system to have an effective anti-tumor response. In the TME, MDSCs are major obstacles to cancer immunotherapy through reducing the anti-tumor efficacy and making tumor cells more resistant to immunotherapy. Therefore, targeting MDSCs treatment becomes the priority of relevant studies and provides new immunotherapeutic strategy for cancer treatment. In this review, we mainly discuss the functions and mechanisms of MDSCs as well as their functional changes in the TME. Further, we review therapeutic effects of immunotherapy against MDSCs and potential breakthroughs regarding immunotherapy targeting MDSCs and immune checkpoint blockade (ICB) immunotherapy.
BibTeX
@inproceedings{sui2022immunotherapy,
  author = {Hongshu Sui and Shengyi Dongye and Xiaocui Liu and Xinghua Xu and Li Wang and Christopher Q. Jin and Minhua Yao and Zhaoqing Gong and Daniel Jiang and Kexin Zhang and Yaling Liu and Hui Liu and Guomin Jiang and Yanping Su},
  title = {{Immunotherapy of targeting MDSCs in tumor microenvironment}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.990463},
}
Figure